There are currently 163 active clinical trials seeking participants for Colorectal Cancer research studies. The states with the highest number of trials for Colorectal Cancer participants are California, Illinois, Ohio and New York.
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
NCT05789069
Recruiting
The purpose of this study is to test the safety and tolerability of HFB200603 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses of HFB200603 as a monotherapy or in combination with tislelizumab until a safe and tolerable dose of HFB200603 as a single agent or combination therapy is determined. During the expansion part, participants will take... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California +10 locations
Conditions: Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Gastric Cancer, Colorectal Cancer
Register for Updates
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
NCT06445062
Recruiting
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel Subprotocol D: RMC-9805 with or without RMC-6236 +... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Mayo Clinic Hospital, Phoenix, Arizona +21 locations
Conditions: Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
NCT06300463
Recruiting
The goal of this clinical trial is to to learn about different combinations of immunotherapy in patients with colorectal cancer whose cancer has spread to their liver and are planning to have surgery to remove tumor metastases from their liver. The main questions it aims to answer are: * whether these combinations of immunotherapy change the tumor microenvironment in the liver * whether these combinations of immunotherapy are safe and effective when used in colorectal cancer with liver metastas... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York
Conditions: Colorectal Cancer Metastatic, Liver Metastases, Colorectal Cancer
Register for Updates
KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
NCT06411691
Recruiting
Phase 1b study evaluating the efficacy and immune response to a synthetic long peptide mutant KRAS vaccine (SPL mKRASvax) combined with Balstilimab and Botensilimab for unresectable or metastatic mismatch repair-proficient (MMR-p) colorectal cancer (mCRC) or unresectable or metastatic MMR-p pancreatic ductal adenocarcinoma (PDAC) patients with measurable disease following first-line chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Colorectal Cancer, Pancreatic Cancer
Register for Updates
Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid
NCT06910670
Recruiting
The overall goal of the randomized control trial (RCT) will be to evaluate the efficacy of modifications to a web-based tool for patient decision-making regarding return of genomic results that will more closely focus on rare cancers. Participants will be given access to a web-based decision aid (or a standard control) that guides participants in making decisions about what type of genomic results they would like to receive from testing performed in the PE-CGS study (NCT06340646).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Cholangiocarcinoma, Colorectal Cancer, Multiple Myeloma
Register for Updates
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
NCT03998202
Recruiting
This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
04/02/2025
Locations: Beebe South Coastal Health Campus, Millville, Delaware +141 locations
Conditions: Colorectal Cancer, Sarcopenia
Register for Updates
Tislelizumab in People With Colorectal Cancer
NCT06529523
Recruiting
The researchers are doing this study to find out whether tislelizumab is an effective treatment for people with colorectal cancer who are living in Nigeria. The researchers will also look at the safety of the study drug. All participants in this study will be treatment naïve (they have not yet received treatment for their cancer), and their cancer will be mismatch repair deficient (dMMR). dMMR cancer can happen when your cells are unable to repair mistakes made during the cell division process. Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York +2 locations
Conditions: Colorectal Cancer
Register for Updates
Ultrasound for the Detection of Oxaliplatin-Induced Peripheral Neuropathy
NCT03958747
Recruiting
This pilot clinical trial studies how well ultrasound works in detecting oxaliplatin-induced neuropathy in patients with gastrointestinal cancer. Ultrasound may work better in diagnosing and detecting neuropathy in gastrointestinal cancer patients treated with the chemotherapy drug called a oxaliplatin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: Gastrointestinal Cancer, Colorectal Cancer
Register for Updates
Stage II/III Colorectal Cancer Recurrence
NCT06314958
Recruiting
This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: City of Hope Medical Center, Monrovia, California +3 locations
Conditions: Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Colorectal Cancer Recurrent
Register for Updates
Predicting Local and Distant Recurrence in T1 Colorectal Cancer
NCT06314971
Recruiting
Tumor recurrence significantly affects survival rates following the local resection of submucosal colorectal cancers (T1 CRC). Despite this, there are currently no reliable biomarkers established to predict recurrence in T1 CRC. This study seeks to improve the prediction of recurrence-free survival in individuals who have survived T1 CRC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: City of Hope Medical Center, Duarte, California +2 locations
Conditions: Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Stage I, Colorectal Neoplasms Malignant, Colorectal Cancer Recurrent
Register for Updates
Improving Care After Inherited Cancer Testing
NCT04763915
Recruiting
The IMPACT Study seeks to refine and evaluate the effectiveness of interventions on improving guideline-adherent cancer risk management (CRM) and family communication (FC) of genetic test results for individuals with a documented pathogenic/likely pathogenic (P/LP) variant, and FC of family cancer history for individuals with a variant of uncertain significance (VUS) in an inherited cancer gene.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Conditions: Inherited Cancer Syndrome, Prostate Cancer, Colorectal Cancer, Endometrial Cancer, Breast Cancer
Register for Updates
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
NCT05787587
Recruiting
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: HonorHealth Research Institute, Phoenix, Arizona +26 locations
Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Nsclc
Register for Updates